ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
YONKERS, N.Y., April 26, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
Richard Roths Media Announces $52 Million Dollar Investment Approval to Expand its AI-Driven Marketing Systems
Four Inc. Secures Spot on Washington Technology’s Top 100 Government Contractors List for 11th Consecutive Year
Tat Hong Equipment Service Co., Ltd. Announces 2025/26 Annual Results